Abiopharma

🔍 O'Brien Patrick (Executive)

Company: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Sold 560 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 526,641.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 560 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 526,081.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 560 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 525,521.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 560 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 524,961.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 560 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: G | equity_swap_involved: 0 | shares_owned_after: 524,401.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,368 shares of Common Stock at $61.2 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 520,033.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5, F2
• Sold 6,164 shares of Common Stock at $62.23 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 513,869.00 | transaction_form_type: 4 | Footnotes: F3, F4, F6, F2
• Sold 13,451 shares of Common Stock at $62.96 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 500,418.00 | transaction_form_type: 4 | Footnotes: F3, F4, F7, F2
• Sold 11,842 shares of Common Stock at $63.84 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 488,576.00 | transaction_form_type: 4 | Footnotes: F3, F4, F8, F2
• Sold 2,700 shares of Common Stock at $64.44 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 485,876.00 | transaction_form_type: 4 | Footnotes: F3, F4, F9, F2
• Sold 900 shares of Common Stock at $66.01 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 484,976.00 | transaction_form_type: 4 | Footnotes: F3, F4, F10, F2
• Sold 313 shares of Common Stock at $68.0 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 484,663.00 | transaction_form_type: 4 | Footnotes: F3, F4, F2
• Sold 600 shares of Common Stock at $61.12 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 484,063.00 | transaction_form_type: 4 | Footnotes: F3, F11, F2
• Sold 900 shares of Common Stock at $62.25 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 483,163.00 | transaction_form_type: 4 | Footnotes: F3, F12, F2
• Sold 5,873 shares of Common Stock at $62.91 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 477,290.00 | transaction_form_type: 4 | Footnotes: F3, F13, F2
• Sold 2,336 shares of Common Stock at $64.04 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 474,954.00 | transaction_form_type: 4 | Footnotes: F3, F14, F2
• Sold 46 shares of Common Stock at $68.0 per share (Direct)
  Date: 2026-01-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 474,908.00 | transaction_form_type: 4 | Footnotes: F3, F2

Footnotes:

• F1: Gift to relatives
• F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
• F3: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F4: Partial disposition of shares to satisfy tax withholding obligations.
• F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F6: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F7: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F8: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F9: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F10: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F11: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F12: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F13: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
• F14: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.